Literature DB >> 28775083

Rare cause of respiratory failure in a young woman: isolated diffuse alveolar haemorrhage requiring extracorporeal membrane oxygenation.

David Kelly1, Damodar Makkuni2, Dhiraj Ail3.   

Abstract

A previously healthy 21-year-old young woman presented with worsening dyspnoea and haemoptysis. Imaging was suggestive of widespread pulmonary haemorrhage. There was no other organ system involvement in particular no evidence of renal involvement. Raised antimyeloperoxidase titres allowed diagnosis of isolated diffuse alveolar haemorrhage (DAH) secondary to microscopic polyangiitis (MPA). The patient rapidly deteriorated with worsening respiratory failure despite invasive mechanical ventilation and required extracorporeal membrane oxygenation (ECMO). This maintained the patient long enough to allow aggressive therapy in the form of immunosuppression and plasma exchange. She made a remarkable recovery and is asymptomatic 2 years on. Isolated DAH in the absence of renal disease is an atypical presentation of MPA and can lead to diagnostic uncertainty. A literature review reveals increasing reports of successful use of ECMO in severe DAH due to pulmonary vasculitis. Despite this, the need for systemic anticoagulation in the presence of pre-existing haemorrhage remains a challenging dilemma. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Adult intensive care; Respiratory medicine; Vasculitis

Mesh:

Year:  2017        PMID: 28775083      PMCID: PMC5612507          DOI: 10.1136/bcr-2017-219235

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  1 in total

Review 1.  The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature.

Authors:  Paolo Delvino; Sara Monti; Silvia Balduzzi; Mirko Belliato; Carlomaurizio Montecucco; Roberto Caporali
Journal:  Rheumatol Int       Date:  2018-08-03       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.